What Does Clene's(NASDAQ:CLNN) NDA Submission for CNM-Au8 Mean for ALS Treatment Prospects?

Sonal Goyal

05 November 2026 12:35 PM AEDT

What Does Clene's(NASDAQ:CLNN) NDA Submission for CNM-Au8 Mean for ALS Treatment Prospects?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Clene submitted a New Drug Application to the FDA in October 2026 seeking Accelerated Approval for CNM-Au8 in amyotrophic lateral sclerosis (ALS).

• The company completed a $4.0 million registered direct offering in September 2026, expected to fund operations through mid-first quarter 2027.

• A Phase 3 RESTORE-ALS confirmatory trial is planned to begin enrolling in the second quarter of 2027.

• Clene reported Q3 2026 Net Income of $3.9 million, compared to a net loss of $8.8 million in the year-ago period.

Clene Inc.(NASDAQ:CLNN), a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases, reported its third quarter 2026 financial results on November 4, 2026. The most notable development during the period was the company's submission of a New Drug Application to the U.S. Food and Drug Administration in October 2026, seeking accelerated approval for CNM-Au8 as a treatment for amyotrophic lateral sclerosis.

NDA Submission and Clinical Background

The NDA for CNM-Au8 is supported by NfL biomarker and clinical data from multiple studies, including the Phase 2 HEALEY ALS Platform Trial and its open-label extension, the Phase 2 RESCUE-ALS Trial, and the NIH-sponsored Expanded Access Protocol for CNM-Au8. CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization.

Clene plans to randomize the first participants in the Phase 3 RESTORE-ALS confirmatory trial in the second quarter of 2027. The trial will evaluate the effect of CNM-Au8 on survival as its primary endpoint, with time to ALS clinical worsening events as a secondary efficacy endpoint. Subject to FDA acceptance of the NDA for review, the company could receive $6.7 million to $7.8 million in proceeds from common stock warrants issued in its January 2026 financing.

Q3 2026 Financial Performance

Clene reported net income of $3.9 million, or $0.30 per basic share, for the quarter ended September 30, 2026. This compares to a net loss of $8.8 million, or $0.85 per basic and diluted share, in the same period a year earlier. The swing to net income was primarily driven by $10.3 million in total other income, net, which reflected a change in Fair Value of common stock Warrant liabilities and derivative liabilities. In the prior-year quarter, total other expense, net, was $3.1 million.

Research and development expenses were $4.4 million for Q3 2026, up approximately 27% from $3.5 million in Q3 2025. The increase was primarily attributed to higher regulatory expenses related to the NDA submission, along with higher Manufacturing and personnel costs. These were partially offset by lower clinical trial expenses for both the ALS and multiple sclerosis programs. General and administrative expenses decreased approximately 10% to $1.9 million, from $2.2 million a year earlier, driven by lower insurance costs, legal fees, and stock-based compensation expenses.

Cash Position and Runway

Cash and cash equivalents stood at $9.9 million as of September 30, 2026, up from $5.2 million at the end of 2025. In September, the company closed a $4.0 million registered direct offering of common stock priced at $3.28 per share, led by Chairman David Matlin along with founding investor Kensington Capital Holdings and existing stockholders including the CEO.

Net cash used in Operating Activities was $11.7 million for the nine months ended September 30, 2026, compared to $13.7 million for the same period in 2025. The company expects that its current resources will provide operating runway through mid-first quarter 2027, indicating a relatively limited cash cushion as it awaits FDA feedback on the NDA.

The Road Ahead

Clene's near-term trajectory hinges on the FDA's response to its NDA submission for CNM-Au8. If the agency accepts the application for review, the company could gain access to additional capital through warrant proceeds. The planned Phase 3 RESTORE-ALS confirmatory trial, set to begin enrollment in Q2 2027, will be a critical milestone in demonstrating whether CNM-Au8 can deliver a survival benefit in ALS patients. With limited cash runway extending only through mid-Q1 2027, the company's ability to secure additional financing will be an important Factor in executing its development and regulatory plans.

FAQs

Q: What is CNM-Au8 and what condition does it target?

A: CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by increasing energy production. Clene has filed for accelerated approval to treat amyotrophic lateral sclerosis (ALS).

Q: What clinical evidence supports the CNM-Au8 NDA?

A: The NDA is supported by NfL biomarker and clinical data from the Phase 2 HEALEY ALS Platform Trial, the Phase 2 RESCUE-ALS Trial, and an NIH-sponsored Expanded Access Protocol.

Q: How long can Clene fund its operations with current resources?

A: The company expects its resources as of September 30, 2026, to fund operations through mid-first quarter 2027.

Q: When will the Phase 3 RESTORE-ALS trial begin?

A: Clene plans to begin randomizing participants in the Phase 3 RESTORE-ALS confirmatory trial in the second quarter of 2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.